Rheumatology

Japanese investigators say more needs to be known about what happens post treatment with biosimilar infliximab in patients with rheumatoid arthritis (RA).

Polpharma Biologics: The Polish Biosimilar Powerhouse

August 11th 2020

By Skylar Jeremias

Article

Now that Polpharma Biologics has fully integrated Bioceros into its brand, the company hopes to become one of the world’s leading biologics manufacturers.

Study: How Out-of-Pocket Caps Affect Payer Policy

August 7th 2020

By Tony Hagen

Article

Investigators set out to learn whether the imposition of out-of-pocket spending caps on specialty drugs would unleash a wave of drug spending and prompt payer policy change.

CinnaGen Biosimilar Shows Promise in Treating COVID-19

August 7th 2020

By Skylar Jeremias

Article

A new study showed that biosimilar interferon beta-1a (IFN-β-1a) may be effective in helping to treat patients with coronavirus disease 2019 (COVID-19).

Samsung Bioepis Appeals to Patients Through Package Design

August 6th 2020

By Tony Hagen

Article

In an award-winning attempt to get closer to patients, Samsung Bioepis has replaced harsh typography with white backgrounds and gentle shapes on its new biosimilar packaging.

Anti-TNF Biologics Outperform in Crohn Disease

August 6th 2020

By Deana Ferreri, PhD

Article

A real-world study on inflammatory bowel disease employing originator and biosimilar biologics suggests anti–tumor necrosis factor (TNF) therapy may be more effective for Crohn disease than for ulcerative colitis.

Teva, Alvotech Partner on Biosimilars for US Market

August 5th 2020

By Skylar Jeremias

Article

Teva Pharmaceutical Industries has expanded on its hopes for a biosimilar comeback with a commercialization deal with Alvotech, which could bring as many as 5 biosimilars to the US market.